Recent research have focused on the convergence of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopaminergic signaling. While GLP activators are commonly employed for managing type 2 diabetes mellitus, their unexpected effects on motivation circuits, specifically governed by DA systems, are gaining subs